Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia by Giacopelli, B. et al.
Journal Articles 
2019 
Developmental subtypes assessed by DNA methylation-iPLEX 
forecast the natural history of chronic lymphocytic leukemia 
B. Giacopelli 
Q. Zhao 
A. S. Ruppert 
A. Agyeman 
C. Weigel 
See next page for additional authors 
Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles 
 Part of the Internal Medicine Commons 
Recommended Citation 
Giacopelli B, Zhao Q, Ruppert AS, Agyeman A, Weigel C, Wu YZ, Gerber MM, Rabe KG, Rai KR, Oakes CC, . 
Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic 
lymphocytic leukemia. . 2019 Jan 01; 134(8):Article 5029 [ p.]. Available from: 
https://academicworks.medicine.hofstra.edu/articles/5029. Free full text article. 
This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic 
Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara 
Zucker School of Medicine Academic Works. For more information, please contact academicworks@hofstra.edu. 
Authors 
B. Giacopelli, Q. Zhao, A. S. Ruppert, A. Agyeman, C. Weigel, Y. Z. Wu, M. M. Gerber, K. G. Rabe, K. R. Rai, C. 
C. Oakes, and +16 additional authors 
This article is available at Donald and Barbara Zucker School of Medicine Academic Works: 
https://academicworks.medicine.hofstra.edu/articles/5029 
12/3/2019 Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC6706807/?report=printable 1/20
Blood. 2019 Aug 22; 134(8): 688–698.
Prepublished online 2019 Jul 10.
doi: 10.1182/blood.2019000490: 10.1182/blood.2019000490
PMCID: PMC6706807
PMID: 31292113
Developmental subtypes assessed by DNA methylation-iPLEX
forecast the natural history of chronic lymphocytic leukemia
Brian Giacopelli,  Qiuhong Zhao,  Amy S. Ruppert,  Akwasi Agyeman,  Christoph Weigel,  Yue-Zhong Wu,
Madelyn M. Gerber,  Kari G. Rabe,  Melissa C. Larson,  Junyan Lu,  James S. Blachly,  Kerry A. Rogers,
William G. Wierda,  Jennifer R. Brown,  Kanti R. Rai,  Michael Keating,  Laura Z. Rassenti,  Thomas J. Kipps,
Thorsten Zenz,  Tait D. Shanafelt,  Neil E. Kay,  Lynne V. Abruzzo,  Kevin R. Coombes,  Jennifer A. Woyach,
John C. Byrd,  and Christopher C. Oakes
Division of Hematology, Department of Internal Medicine, and
Department of Pathology, The Ohio State University, Columbus, OH;
Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic,
Rochester, MN;
European Molecular Biology Laboratory, Heidelberg, Germany;
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX;
Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA;
Division of Hematology-Oncology, North Shore–Long Island Jewish Medical System, New Hyde Park, NY;
Department of Medicine, University of California San Diego, La Jolla, CA;
Department of Medical Oncology and Hematology, University Hospital and University of Zürich, Zürich,
Switzerland;
Department of Medicine-Hematology, Stanford School of Medicine, Stanford, CA;
Division of Hematology, Mayo Clinic, Rochester, MN; and
Department of Biomedical Informatics and
Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH
Corresponding author.
Received 2019 Mar 7; Accepted 2019 Jul 3.
Copyright © 2019 by The American Society of Hematology
Key Points
The Me-iPLEX assay is an accurate and robust method for efficiently measuring multiplexed panels
of DNA methylation sites.
Me-iPLEX–determined epitypes stratify risk, regardless of CLL disease progression or treatment
with chemoimmunotherapy or ibrutinib.
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Alterations in global DNA methylation patterns are a major hallmark of cancer and represent attractive
biomarkers for personalized risk stratification. Chronic lymphocytic leukemia (CLL) risk stratification
studies typically focus on time to first treatment (TTFT), time to progression (TTP) after treatment, and
overall survival (OS). Whereas TTFT risk stratification remains similar over time, TTP and OS have
changed dramatically with the introduction of targeted therapies, such as the Bruton tyrosine kinase
inhibitor ibrutinib. We have shown that genome-wide DNA methylation patterns in CLL are strongly
associated with phenotypic differentiation and patient outcomes. Here, we developed a novel assay, termed
methylation-iPLEX (Me-iPLEX), for high-throughput quantification of targeted panels of single cytosine
guanine dinucleotides from multiple independent loci. Me-iPLEX was used to classify CLL samples into 1
of 3 known epigenetic subtypes (epitypes). We examined the impact of epitype in 1286 CLL patients from
4 independent cohorts representing a comprehensive view of CLL disease course and therapies. We found
that epitype significantly predicted TTFT and OS among newly diagnosed CLL patients. Additionally,
epitype predicted TTP and OS with 2 common CLL therapies: chemoimmunotherapy and ibrutinib.
Epitype retained significance after stratifying by biologically related biomarkers, immunoglobulin heavy
chain mutational status, and ZAP70 expression, as well as other common prognostic markers.
Furthermore, among several biological traits enriched between epitypes, we found highly biased
immunogenetic features, including IGLV3-21 usage in the poorly characterized intermediate-programmed
CLL epitype. In summary, Me-iPLEX is an elegant method to assess epigenetic signatures, including
robust classification of CLL epitypes that independently stratify patient risk at diagnosis and time of
treatment.
Visual Abstract
Introduction
Chronic lymphocytic leukemia (CLL) is a B-cell malignancy with a highly variable disease course.  At
diagnosis, the majority of CLL patients are asymptomatic. Observation without treatment until
symptomatic disease progression is standard clinical practice; however, risk stratification to identify
patients who are likely to progress quickly to symptomatic CLL and have an inferior survival is often used.
Many studies have been published with different biomarkers predicting time to first treatment (TTFT) and
overall survival (OS). Most widely used in this setting are assessment of interphase cytogenetics,
mutational status of TP53, serum β2 microglobulin, and immunoglobulin heavy chain (IGHV) somatic
mutation status, along with the Rai or Binet staging system.  IGHV mutational status is an important
robust individual prognostic marker and relates to whether the founder CLL cell clone is of pre- or
postgerminal origin.  IGHV-unmutated (IGHV-U) CLL generally displays a more aggressive clinical
course, whereas IGHV-mutated (IGHV-M) CLL generally displays an indolent clinical course.  Less
laborious IGHV surrogate markers, such as ZAP70 protein expression and methylation, were subsequently
developed and were also found to be strongly associated with outcomes.
For many years, treatment of CLL consisted of chemoimmunotherapy (CIT) with fludarabine,
cyclophosphamide, and rituximab (FCR) in young patients,  and chlorambucil with obinutuzumab in older
patients.  Treatment risk stratification uses del(17)(p13.1) to direct patients to alternative treatments.
IGHV mutational status is also used in this setting to predict eventual progression with CIT ; IGHV-M
patients are more likely to have durable prolonged remissions with presumed cure.  The introduction of
the Bruton tyrosine kinase inhibitor ibrutinib has changed the CLL landscape, with broad clinical activity
across all genomic subtypes.  However, patients with complex karyotype, del(17)(p13), TP53
mutations, and multiple prior treatments have a higher progression rate than those who are untreated or
lack these genomic features,  although recent phase 3 studies have demonstrated that ibrutinib is still
superior compared with standard CIT in this high-risk group.  Improvement in risk stratification to
identify patients who are likely to achieve durable responses with both therapy types is needed.
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DNA methylation is a stable, yet reversible, epigenetic modification involving the covalent addition of a
methyl group to the 5′ carbon of cytosine in cytosine guanine dinucleotide (CpG). It is critical for
regulating gene expression, and perturbations are common in diseases such as cancer.  Because of its
stability over time, DNA methylation is used for cancer therapy–guiding biomarkers.  In CLL, a distinct
genome-wide DNA methylation pattern defines 3 epigenetic subgroups that are correlated with IGHV
status and clinical outcomes.  We term these “epitype” subgroups high-programmed CLL (HP-CLL),
intermediate-programmed CLL (IP-CLL), and low-programmed CLL (LP-CLL) based on their
relationship to B-cell maturation.  CLL epitype remains unchanged during disease course and exhibits a
similar longitudinal stability as IGHV mutation status.  Because of the large degree of redundancy
in epigenetic signatures between epitypes, DNA methylation patterns initially observed using genome-
wide analyses can be recapitulated using reduced panels of CpGs.
Methodologies for measuring DNA methylation range from whole-genome and global assays to various
targeted approaches.  Targeted assays, such as pyrosequencing, methylation-sensitive quantitative
polymerase chain reaction (PCR), and EpiTYPER MassARRAY, measure single CpGs or single small
regions of interest. Currently, there is a need for methods of midrange capacity that are capable of
analyzing multiplexed single CpG methylation from multiple genomic loci in a high-resolution and high-
throughput manner. Here, we introduce the methylation-iPLEX (Me-iPLEX) method that uses multiplexed
PCR on bisulfite-converted DNA, followed by readout using matrix-assisted laser desorption/ionization
time-of-flight (MALDI-TOF) mass spectrometry on the MassARRAY system.  We evaluated the
utility of Me-iPLEX to classify CLL into its 3 known epitypes in 1286 CLL samples from 4 independent
CLL cohorts for risk stratification of newly diagnosed patients, as well as CIT- and ibrutinib-treated
patients, to predict time to treatment and treatment-response duration.
Methods
Patient samples and data
We investigated 4 independent patient sample cohorts with differing overall characteristics and treatment
(supplemental Table 1, available on the Blood Web site). The Mayo Clinic (Mayo; n = 248) cohort
included samples from treatment-naive CLL patients collected at diagnosis. The MD Anderson Cancer
Center (MDACC; n = 367) cohort samples were obtained from treatment-naive patients who subsequently
required treatment, with 201 receiving FCR CIT.  MDACC samples were enriched by immunomagnetic
separation from peripheral blood mononuclear cells (PBMCs; n = 278) or extracted from formalin-fixed
paraffin-embedded (FFPE) bone marrow clot sections (n = 89). The Ohio State University ibrutinib (OSU-
ibrutinib; n = 232) cohort was composed of relapsed/refractory (R/R) patients (median of 3 prior therapies)
receiving single-agent ibrutinib in clinical trials conducted at The Ohio State University.  Finally, the
CLL Research Consortium (CRC; n = 439) cohort represents samples from untreated patients. Illumina
450K data used for selection of CpGs and training/validation of the epitype prediction model were
obtained from previous publications.  Non-CLL B-cell malignancy samples were obtained from The
Ohio State University Comprehensive Cancer Center (OSUCCC) Leukemia Tissue Bank. All samples
were obtained from blood after patients provided written informed consent in accordance with established
Institutional Review Board guidelines.
Me-iPLEX assay design and method
To assign CLL samples into methylation subgroups, we selected 7 loci displaying methylation states that
were most significantly associated with the 3 methylation subgroups, as defined by consensus clustering of
Illumina 450K data,  including the ZAP70 promoter region.  CpGs used in assessing sample purity and
composition were selected from Illumina 450K profiles of purified healthy hematopoietic subsets.  To
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classify samples into epitypes, we used a random forest algorithm modified from Capper et al  trained
using Me-iPLEX values from 20 genomic loci generated on the training set.  This generated a calibrated
probability class call of HP-CLL, IP-CLL, LP-CLL, or normal PBMCs. Call probabilities <0.9 were
labeled as ambiguous. We used internal cross-validation and an external validation sample set to evaluate
accuracy with known epitype calls determined from Illumina 450K classification.  Additional details are
found in supplemental Methods.
Results
Simultaneous interrogation of DNA methylation from multiple loci using Me-iPLEX
To efficiently assess the DNA methylation level of a targeted panel of CpGs for use in epigenetic
classification, we sought an approach that could accurately quantify methylation levels at single-CpG
resolution in a multiplex format. In the Me-iPLEX approach, DNA is subjected to sodium bisulfite, and
genomic regions of interest are amplified in a multiplex capture PCR (Figure 1). Targeted cytosines are
interrogated with a single-base extension to measure a quantitative ratio of unmethylated/methylated
cytosine by MALDI-TOF using the MassARRAY system. To evaluate the accuracy of Me-iPLEX, we
compared the methylation values with other established methods for measuring DNA methylation at
single-CpG resolution, including the EpiTYPER assay and Illumina 450K arrays. We found that Me-
iPLEX methylation values were highly reproducible and concordant with other methods (supplemental
Figure 1).
Construction of a novel methylation classifier compatible with impure CLL samples
Using our previously published and other publicly available Illumina 450K array data on CLL and normal
purified PBMC subpopulations, we identified a subset of CpGs that exhibited unique DNA methylation
patterns in each of the 3 CLL epitypes  compared with healthy cell populations (Figure 2A), including
CpGs that distinguish T/natural killer (NK) cell and myeloid cell types. Because non-CLL PBMCs carry
DNA methylation patterns that would systematically obscure epitype classification, we aimed to construct
an assay that could determine the CLL epitype in the presence of contaminating non-CLL cells. We
identified 20 genomic regions and targeted 34 CpGs by using 40 extension primers across 3 multiplexed
PCR reactions (supplemental Table 2). These combine to create a unique pattern for each CLL epitype and
potential contaminating cell type.
To classify samples into 1 of 4 methylation classes (HP-CLL, IP-CLL, LP-CLL, or normal PBMCs), we
trained a random forest regression model. The model was initially trained on 139 samples of known CLL
epitype, as determined by Illumina 450K data, and normal PBMC samples (healthy donor or CLL-depleted
PBMCs). Using the random forest model incorporating Me-iPLEX methylation data from all 139 training
samples, we generated an aggregate raw class score and fit a multinomial logistic regression calibration
model to obtain a class probability for each sample (Figure 2B, see “Methods”). Visual inspection of the
relationships among methylation patterns across samples using t-distributed stochastic neighbor
embedding (t-SNE) showed clear separation of samples into epitypes (Figure 2C). Random cross-
validation of the training model demonstrated the strong discriminating power of the classifier (Figure 2A;
supplemental Figure 2A). For further validation, we interrogated an independent set of 166 CLL samples
of known epitype  and achieved 100% accuracy in the validation cohort based on the model generated
using the training set (Figure 2D; supplemental Figure 2B). For the purposes of interrogating subsequent
test samples, we combined our training and validation cohorts to create a reference cohort that further
maximizes the robustness of the classifier (supplemental Figure 2C-D).
Technical evaluation of the Me-iPLEX CLL epitype classifier
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To determine the lower limit of tumor purity required for epitype classification, we mixed DNA from
purified CLL samples with DNA isolated from healthy donor PBMCs at fixed ratios. The calibrated score
for the corresponding correct subtype fell below the conservative 0.9 probability cutoff at roughly 60%
CLL DNA content for all 3 epitypes (supplemental Figure 3A). The DNA methylation pattern from
samples with <60% CLL content more closely resembled that of healthy PBMCs and was classified as
impure. To confirm this lower purity boundary, impure CLL samples were separated into purified CLL and
CLL-depleted fractions using CD19  magnetic cell separation. The cell populations were then mixed back
together at known ratios and confirmed by flow cytometry. Again, a high-confidence epitype probability >
0.9 was observed if CLL cells made up >60% of the sample (supplemental Figure 3B). The methylation
pattern of CLL-depleted fractions matched that of a healthy PBMC sample. We developed a simple
estimate of CLL purity using CpGs with CLL-specific methylation in samples of fixed CLL content by
fitting a nonlinear equation to estimate the CLL purity of test samples (supplemental Figure 3C). To
determine the minimum amount of input DNA required to confidently assign an epitype, we made serial
dilutions of CLL DNA from all 3 epitypes (n = 8 samples per epitype). The subtype call remained stably
>0.9 probability when ≥1 ng of DNA was used (approximately ≥200 cells), indicating that the assay can
reliably assign the correct subtype with relatively low input (supplemental Figure 3D). Analysis of DNA
derived from FFPE bone marrow clot sections and fresh-frozen samples from the same patient resulted in
identical epitype calls (supplemental Table 3).
Determining epitypes in multiple CLL cohorts using Me-iPLEX
The high-throughput nature of the Me-iPLEX assay enables the efficient analysis of a large number of
CLL samples. We evaluated 4 independent CLL patient sample cohorts (N = 1286) with varying patient
features and treatments (Figure 3; supplemental Figure 4). Overall, 49%, 13%, and 21% of CLL samples
were classified as LP-CLL, IP-CLL, and HP-CLL, respectively, and 7% displayed insufficient tumor
purity. CLL samples with sufficient purity but that fell below the 0.9 probability threshold were termed
“ambiguous” and ranged from 6% to 14% per cohort. Visualizing methylation patterns by t-SNE showed
that CLL sample impurity was increased at the periphery of clusters, intensifying toward the cluster
containing normal PBMC training samples (supplemental Figure 5A). Samples with lower probability
scores were located between and at the periphery of t-SNE clusters (supplemental Figure 5B). Ambiguous
samples commonly exhibited methylation patterns that fell between high-confidence epitype clusters,
consistent with the notion of a continuum of methylation states in CLL,  and displayed intermediate
clinical risk, as expected from mixed epitypes (data not shown). Ambiguous samples showed normal CLL
immunophenotypic features, as measured by Matutes score  (supplemental Figure 5C). A minor cluster of
samples simultaneously displayed low CLL purity and low probability of a PBMC epitype (supplemental
Figure 5A-B), which we reasoned may represent atypical CLL or patients with a non-CLL malignancy. To
test this, we analyzed a collection of 49 non-CLL samples, including mantle cell lymphoma, marginal zone
lymphoma, hairy cell leukemia, and B-cell prolymphocytic leukemia, using the Me-iPLEX assay and
found that the majority of non-CLL samples clustered in or nearby the atypical cluster (supplemental
Figure 5D). Indeed, CLL samples in the atypical cluster showed a lower Matutes score (2-3) compared
with high-confidence epitypes (mean scores 4.3, 4.1, and 4.2 for HP-CLL, IP-CLL, and LP-CLL,
respectively) (supplemental Figure 5C). Sixty-eight percent of non-CLL samples were deemed ambiguous
or impure, demonstrating that, along with atypical samples, non-CLL samples will often fail CLL epitype
classification (supplemental Figure 5E-F). These results demonstrate that Me-iPLEX can classify CLL
epitypes in a large majority of samples with high confidence, while identifying impure samples and non-
CLL methylation patterns that would not be detected by other approaches.
Distinct features of CLL epitypes
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Combining available feature data for all training, validation, and test cohorts (N = 1578 samples), we
performed a high-resolution assessment of biological and clinical features associated with epitype, paying
special attention to the less frequent IP-CLL group. The most remarkable biological traits enriched among
epitypes pertained to immunoglobulin features and somatic mutations (supplemental Table 4). IP-CLL
patients displayed a distinct intermediate degree of IGHV mutations (mean, 95.9%) relative to LP-CLL
and HP-CLL (99.7% and 92.7%, respectively) (Figure 4A). IP-CLL predominantly used VH3 family genes
(65% of IP-CLL), including VH3-21 and VH3-23, whereas VH usage by HP-CLL was predominated by
VH3-7 and VH4-34, and LP-CLL most commonly used VH1-69 (Figure 4B). Interestingly, IP-CLL
exhibited a distinct, but nonexclusive, usage of λ immunoglobulin light chains (P < .0001) (Figure 4C).
Assessing specific light chain gene usage available for the OSU-ibrutinib and validation cohorts, we found
that more than half of IP-CLL samples used IGLV3-21 rearrangements (P < .0001 (Figure 4D). With the
exception of trisomy 12, cytogenetic abnormalities were unequally distributed across epitypes (Figure 4E).
Deletions on chromosomes 17p and 11q, encompassing TP53 and ATM, respectively, were enriched in LP-
CLL, whereas deletion of 13q (DLEU2) was more frequent in IP-CLL. NOTCH1 and TP53 mutations were
enriched in LP-CLL, with XPO1 mutations virtually specific for this epitype (Figure 4F). In addition to
confirming that SF3B1 mutations occur more frequently in IP-CLL, we have identified that mutated
MYD88 is most frequently found in IP-CLL. As of the last follow-up, Richter’s Transformation (RT) was
available for the MDACC and OSU-ibrutinib cohorts, with 13 and 10 cases of RT observed, respectively.
Of the 23 RT cases, 1 was of insufficient purity, 1 was ambiguous, 14 were LP-CLL, 7 were IP-CLL, and
none were HP-CLL. HP-CLL displayed significantly less risk for RT (P = .010), whereas IGHV mutation
status was not significant. We next combined all patients not treated at sampling (Mayo, CRC, and
MDACC cohorts) and found that outcomes for IP-CLL patients were significantly different compared with
the LP-CLL and HP-CLL groups for TTFT and OS (supplemental Figure 6).
Prognostic impact of epitype at various natural history time points
We sought to comprehensively evaluate the prognostic significance of Me-iPLEX–determined CLL
epitypes across disease stages. Because many CLL patients are not treated immediately at diagnosis, and
some patients may never require therapy, we first investigated whether epitype would predict TTFT. The
Mayo cohort is a population of CLL patients with confirmed initial diagnosis at the Mayo Clinic and
sampling at diagnosis. We found that epitype predicted an extended TTFT for HP-CLL cases, with >50%
of patients untreated at 6 years following diagnosis (Figure 5A). Furthermore, for HP-CLL patients
requiring therapy, treatment was delayed significantly (P = .0008; median difference, 2.2 years) relative to
IP-CLL and LP-CLL. We next sought to investigate whether epitype predicts response to therapy in front-
line and R/R settings, as well as in response to traditional CIT and the novel therapy, ibrutinib. In the
MDACC cohort, 201 patients with epitype data were uniformly treated with FCR as front-line therapy.
Following treatment with FCR, HP-CLL patients experienced a significantly longer time to progression
(TTP), with 75% remaining treatment-free at 10 years (Figure 5B). We next explored whether epitype is
associated with outcome in R/R patients following treatment with ibrutinib. The OSU-ibrutinib cohort is
composed of patients treated with a median of 3 prior therapies who subsequently received ibrutinib.  As
would be expected in a cohort of patients who have failed multiple prior therapies, we found that the more
clinically aggressive LP-CLL epitype is predominant (74.8%). Nonetheless, we observed a significantly
reduced cumulative incidence of ibrutinib discontinuation as the result of CLL progression or RT in HP-
CLL patients (Figure 5C). Next, we examined the impact of epitype on OS in each cohort and found that
HP-CLL cases exhibited significantly longer OS following FCR treatment (MDACC) and ibrutinib, as
well as a trend toward longer OS in the Mayo cohort (from diagnosis), likely as a result of the shorter
follow-up duration (Figure 5D-F). These results show that the CLL epitype can be useful prior to and
throughout the treatment course in patients treated with CIT or ibrutinib.
Prognostic impact of epitype compared with other markers of CLL founder cell subtype
18
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Because epitype, IGHV status, and ZAP70 expression similarly derive from the degree of differentiation of
the founder cell, and epitype remains comparably unchanged over disease course, we sought to compare
these 3 related features. Indeed, these features were highly concordant, with 95.7% of LP-CLLs exhibiting
IGHV-U and 88.1% of HP-CLLs exhibiting IGHV-M across all samples (supplemental Table 1). Similarly,
65.5% of LP-CLLs were ZAP70 , and 75.8% of HP-CLLs were ZAP70 . Because patients discordant for
the above common epitype and IGHV or ZAP70 relationships represented a minor proportion of cases, we
again combined patients from the 3 cohorts (Mayo, CRC, and MDACC) who were untreated at sampling.
To increase the proportion of potential discordant cases, the CRC cohort was supplemented with 192
patients who displayed discordant IGHV and ZAP70 markers. After stratifying patients separately by
IGHV mutation status and ZAP70 expression, we observed that epitype remained significantly associated
with TTFT in ZAP70 , ZAP70 , IGHV-M, and IGHV-U patients (Figure 6A). Epitype consistently
retained prognostic significance for OS in all 4 subgroups (Figure 6B). Interestingly, the HP-CLL epitype
rescued IGHV-U patients from an unfavorable OS outcome, with very few deaths occurring with this
combination relative to IGHV-U/LP-CLL. Likewise after separating by ZAP70 status, epitype maintained
significant separation of OS. Although limited by sample size, we identified 2 IGHV-U patients with an
HP-CLL epitype, and they displayed a relatively longer survival (supplemental Figure 7). For each cohort,
a multivariable analysis was performed that specifically included IGHV, ZAP70, and epitype
(supplemental Table 5). The 3 features were broadly significant as single variables across cohorts, yet
epitype was the sole variable that retained significance in multivariable models for TTFT (Mayo, CRC
cohorts), time to ibrutinib discontinuation due to disease (OSU-ibrutinib cohort), and OS (CRC and OSU-
ibrutinib cohorts). Given the high degree of correlation among IGHV, ZAP70, and epitype, and that only
epitype retained statistical significance when all 3 features were included in the same model, we retained
epitype in further multivariable modeling that incorporated age, gender, Rai stage, and the high-risk
cytogenetic abnormality del(17p). Epitype retained statistical significance for TTFT, TTP, and ibrutinib
discontinuation, as well as for OS, in the MDACC and OSU-ibrutinib cohorts (supplemental Table 6).
Together, these results suggest that epitype, as measured by Me-iPLEX, is a superior predictor of outcomes
relative to related features IGHV and ZAP70, and it retains independence when included with other
common CLL prognostic markers to predict outcomes with CIT or ibrutinib.
Discussion
In this study, we have developed a novel method, Me-iPLEX, and applied it to evaluate CLL epitypes
previously identified by our group.  We found that epitype is associated with distinct biological features
and consistently predicts CLL patient outcomes in 4 independent sample cohorts. Me-iPLEX–determined
epitype demonstrated associations with clinical outcomes, independently of other biologically related
factors, IGHV mutation status, and ZAP70 expression, as well as other common prognostic markers, and it
is the superior factor in identifying patients who are more likely to respond to traditional CIT. We have
also found that epitype is a significant prognostic factor for TTP and OS in relapsed patients treated with
ibrutinib. Few biomarkers are correlated with survival when using novel agents in CLL; studies have
identified the significant impact of TP53 disruption and genomic instability.  We show that epitype is
prognostic in patients treated with CIT or ibrutinib, demonstrating clinical relevance in the current
therapeutic era.
The Me-iPLEX assay is a novel approach to analyze single CpG methylation. By using a multiplex format,
Me-iPLEX reduces the per-sample cost and DNA input compared with genome-wide approaches, as well
as other targeted methylation analyses, such as pyrosequencing and EpiTYPER/MassARRAY. Because
Me-iPLEX uses the MassARRAY system, DNA methylation data can be produced from a DNA sample in
a single workday and do not require extensive data processing. The assay could be readily applied to any
application for which the generation of quantitative DNA methylation data on tens to hundreds of CpGs
simultaneously would be desired. We found that the Me-iPLEX assay is highly reproducible and accurate
+ −
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25
14,36
12/3/2019 Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC6706807/?report=printable 8/20
relative to other methods, including when FFPE-extracted DNA was used. Thus, we envision many uses
for Me-iPLEX, including as a useful approach for high-throughput analysis of panels of key CpG sites
derived from genome-wide methylation data.
CLL epitypes were first demonstrated by Kulis and colleagues ; a subsequent targeted panel of 5 CpGs
based on pyrosequencing was developed to discern CLL epitypes and validated in a cohort of 97
patients.  The Me-iPLEX CLL epityping assay improves the robustness of CLL epitype classification by
recognizing samples with critically low CLL content and identifying atypical methylation patterns that
would otherwise have been erroneously assigned an epitype. This is advantageous in clinical settings in
which purification of CLL samples is not generally done, and identification of anomalous DNA
methylation patterns may help point to alternative diagnoses in cases with atypical features. Purification
can be done on selected low-purity samples within a cohort, because we obtained high-confidence epitype
calls following purification in test samples. We also observed that a small minority of samples retained
sufficient purity but fell below the confidence cutoff for epitype classification. This reflects the continuum
of differentiation states that exists in the CLL population ; thus, a small proportion of samples fall
between clusters, although most patients fall within the patterns associated with 1 of the 3 epitypes.
Our investigation, which included a total of 1578 patients, provides a high-resolution association of
biological features with epitypes. We confirmed previous findings of IGHV mutation status and
rearrangements (VH1-69, VH3-23, and VH4-34 in LP-CLL, IP-CLL, and HP-CLL, respectively)
and uncovered additional associations (supplemental Table 4). Interestingly, IP-CLL was heavily biased to
λ light chain usage that extends beyond the association of IGHV3-21/IGLV3-21 cases (known as subset
#2 ) uncovered by Bhoi et al,  because we found that 48% of λ usage was non-IGLV3-21, and only 6 of
24 patients showed simultaneous IGHV3-21/IGLV3-21 rearrangements in IP-CLL. Identification of light
chain use was only available for the OSU-ibrutinib and validation cohorts; IGLV3-21 usage within IP-CLL
was highest in the OSU-ibrutinib cohort (13/20, 65%) and was somewhat lower in the validation cohort
(11/25, 44%). Because IGLV3-21 usage is associated with unfavorable outcome,  higher usage in the
OSU-ibrutinib cohort may be due to the R/R nature of the cohort and may also explain the shift in IP-CLL
curves toward LP-CLL in the OSU-ibrutinib cohort outcome analyses. For genetic aberrations, we
confirmed enrichment of del(11)(q23) and NOTCH1 mutations in LP-CLL  and clarified borderline
significance or uncovered novel associations for del(17p), del(13q), SF3B1, TP53, MYD88, EGR2, and
XPO1 genetic alterations. IP-CLL patients displayed unique patterns of immunoglobulin features and
genetic aberrations representing a unique subgroup rather than a mixture of LP-CLL and HP-CLL.
Interestingly, mantle cell lymphoma frequently exhibited an IP-CLL–like epitype (supplemental Figure
5F), as well as preferential use of λ light chains and enrichment of VH3-21 in IGHV-mutated cases (93-
98% of germline),  suggesting a potential shared pathway and/or origin with IP-CLL.
The choice of CIT vs other potentially noncurative therapy is especially relevant among younger patients.
The clinical impact of epitype on disease progression has not been previously evaluated in cohorts
uniformly treated with FCR or ibrutinib. We observed a plateau of long-term progression-free response at
10 years involving 75% of HP-CLL patients, which improves upon using IGHV-M alone in our study and
in a previous study using a similar sample cohort.  Although epitype remains to be prospectively
evaluated, our data suggest that epitype may help to stratify patients for early intervention with novel
agents. Previous studies of ibrutinib-treated patients failed to detect an impact of IGHV mutation status.
We found that epitype shows a significant impact and independence from IGHV following ibrutinib
treatment, although validation in future studies will be needed. Moving forward, epitype may become a
key component in prognostic index models, together with other epigenetic, genetic, immunophenotypic,
and clinical features.
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The online version of this article contains a data supplement.
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Figure 1.
Open in a separate window
Me-iPLEX workflow. Upon treatment with sodium bisulfite, cytosines will remain as cytosines if methylated (black
lollipop) or will be converted to a uracil if unmethylated. A multiplexed capture PCR amplifies regions surrounding CpGs
of interest (uracil is replaced by thymine in PCR). Primers are annealed immediately 5′ to CpGs of interest, followed by a
single-base extension PCR using terminator nucleotides. Extension products differ in mass according to the extended
base, consistent with the CpG methylation status in the original DNA sample. Relative abundance of extension products is
measured by MALDI-TOF mass spectrometry. Multiple extension products with unique masses can be combined into the
same multiplexed reaction.
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Figure 2.
Epigenetic classification of CLL using Me-iPLEX. (A) Heat map identifying the most differentially methylated CpGs
among CLL epitypes and between CLL and normal cell types using Illumina 450K arrays. The 500 most variable 450K
probes among the 3 CLL epitypes (top row). The 100 most differentially methylated probes comparing CLL with normal
cells, myeloid cells, or T/NK cells (lower rows). Columns represent CLL patients (n = 310), normal myeloid cells (n =
36), normal T/NK cells (n = 12), and normal PBMCs (n = 20). (B) Density plots showing the distribution of the raw
random forest score (upper panel) and the calibrated probability (lower panel) of each methylation class in our training
sample set (n = 139). (C) Unsupervised clustering using a t-SNE plot of the training cohort samples. Colors represent the
calibrated subtype call. (D) Confusion matrix comparing the known epitype call (determined from Illumina 450K
analysis) with the epitype call by the random forest method of the training cohort (upper panel) and with the validation
cohort (lower panel, n = 149).
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Figure 3.
Epityping of CLL patients from 4 independent sample cohorts using Me-iPLEX. (A) Distribution of the calibrated
epitype calls within each of the cohorts. (B) Unsupervised clustering of Me-iPLEX data from CLL samples from 4
independent test cohorts (circles, n = 1286) and from the combined reference cohort (squares, n = 305) using t-SNE.
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Figure 4.
Distinct features of CLL epitypes revealed in combined analysis including all cohorts. (A) Epitype-specific
distribution of IGHV mutations across 1095 patients (P < .0001). (B) Frequency of VH gene usage within epitype among
the 16 most represented VH genes across all cohorts. (C) Frequency of immunoglobulin light chain usage within epitypes
showing distinct usage of IGLV in IP-CLL (P < .0001). (D) Frequency of specific immunoglobulin light chain usage
within epitypes among the 11 most frequent rearrangements. (E) Frequency of cytogenetic abnormalities by FISH within
epitypes. (F) Frequency of most common recurrently mutated genes in CLL within epitypes. *P < .05, **P < .001, ***P <
.0001, χ  test with Bonferroni correction.2
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Figure 5.
Clinical impact of CLL epitypes, as determined by Me-iPLEX, at different phases of CLL disease progression and
treatment. (A) Kaplan-Meier analysis of TTFT of the Mayo cohort comprising patients sampled at diagnosis separated by
epitype. (B) Kaplan-Meier analysis of TTP after uniform treatment with FCR in the MDACC cohort. (C) Cumulative
incidence of ibrutinib discontinuation due to CLL progression or RT, from the time of initiating ibrutinib treatment in the
OSU-ibrutinib cohort. (D) OS from diagnosis in the Mayo cohort. (E) OS from initiation of therapy in FCR-treated
patients from the MDACC cohort. (F) OS from the initiation of ibrutinib therapy in the OSU-ibrutinib cohort. The P
values were assessed using the log-rank test.
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Figure 6.
Open in a separate window
Relative clinical impact of epitype on CLL patient outcomes after separating patients by the related markers
IGHV mutation status and ZAP70 positivity. (A) Patients were combined from the Mayo, CRC, and MDACC cohorts,
and TTFT was plotted by epitype after segregating into 2 groups according to ZAP70 expression (±20% positivity, left
panels) and IGHV status (±98% identity, right panels). (B) The same analysis as in (A), assessing OS from diagnosis. The
P values were assessed using the log-rank test.
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